These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25579712)

  • 1. Relationship between asymmetric dimethylarginine plasma level and left ventricular mass in hemodialysis patients.
    El Shahawy Y; Soliman Y; Rifaie A; Shenawy H; Behairy M; Mady G
    Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):26-33. PubMed ID: 25579712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end‑stage renal disease treated with hemodialysis.
    Napora M; Graczykowska A; Próchniewska K; Zdrojewski Z; Całka A; Górny J; Stompór T
    Pol Arch Med Wewn; 2012; 122(5):226-34. PubMed ID: 22538734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients.
    Ebinç FA; Erten Y; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Mutluay R; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(4):401-6. PubMed ID: 18569913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.
    Zoccali C; Mallamaci F; Maas R; Benedetto FA; Tripepi G; Malatino LS; Cataliotti A; Bellanuova I; Böger R;
    Kidney Int; 2002 Jul; 62(1):339-45. PubMed ID: 12081596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease.
    Bartnicki P; Kowalczyk M; Franczyk-Skóra B; Baj Z; Rysz J
    Curr Vasc Pharmacol; 2016; 14(4):360-7. PubMed ID: 26759218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
    J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels.
    Uzun H; Konukoglu D; Besler M; Erdenen F; Sezgin C; Muderrisoglu C
    Clin Invest Med; 2008; 31(1):E1-7. PubMed ID: 18312743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The differences of asymmetric dimethylarginine removal by different dialysis treatments.
    Zhang DL; Liu J; Liu S; Zhang Y; Liu WH
    Ren Fail; 2010; 32(8):935-40. PubMed ID: 20722560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease.
    Shi B; Ni Z; Zhou W; Yu Z; Gu L; Mou S; Fang W; Wang Q; Cao L; Yan Y; Qian J
    Eur J Intern Med; 2010 Oct; 21(5):444-8. PubMed ID: 20816602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.
    Thaha M; Widodo ; Pranawa W; Yogiantoro M; Tomino Y
    Clin Nephrol; 2008 Jan; 69(1):24-32. PubMed ID: 18226399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding.
    Kielstein JT; Böger RH; Bode-Böger SM; Martens-Lobenhoffer J; Lonnemann G; Frölich JC; Haller H; Fliser D
    Clin Nephrol; 2004 Oct; 62(4):295-300. PubMed ID: 15524060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study.
    Chang JW; Lee EK; Kim TH; Min WK; Chun S; Lee KU; Kim SB; Park JS
    Am J Nephrol; 2007; 27(1):70-4. PubMed ID: 17259696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Frölich JC; Haller H; Ritz E; Fliser D
    J Am Soc Nephrol; 2002 Jan; 13(1):170-176. PubMed ID: 11752034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma asymmetric dimethylarginine, L-arginine and left ventricular structure and function in a community-based sample.
    Lieb W; Benndorf RA; Benjamin EJ; Sullivan LM; Maas R; Xanthakis V; Schwedhelm E; Aragam J; Schulze F; Böger RH; Vasan RS
    Atherosclerosis; 2009 May; 204(1):282-7. PubMed ID: 18829028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organic nitrates favor regression of left ventricular hypertrophy in hypertensive patients on chronic peritoneal dialysis.
    Li H; Wang S
    Int J Mol Sci; 2013 Jan; 14(1):1069-79. PubMed ID: 23296279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients.
    Coen G; Mantella D; Sardella D; Beraldi MP; Ferrari I; Pierantozzi A; Lippi B; Di Giulio S
    J Nephrol; 2009; 22(5):616-22. PubMed ID: 19809994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in left ventricular filling parameters before and after dialysis in patients with end stage renal disease.
    Ersbøll M; Raja AA; Warming PE; Nielsen TL; Plesner LL; Dalsgaard M; Schou M; Rydahl C; Brandi L; Iversen K
    Int J Cardiovasc Imaging; 2019 Sep; 35(9):1673-1681. PubMed ID: 31093896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between serum asymmetric dimethylarginine and blood pressure in patients with chronic renal failure].
    Zhang WR; Tao LJ; Chen BM
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):133-4. PubMed ID: 12575339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease.
    Zoccali C; Benedetto F; Mallamaci F; Tripepi G; Cutrupi S; Pizzini P; Malatino LS; Bonanno G; Seminara G
    J Hypertens; 2006 Oct; 24(10):2039-46. PubMed ID: 16957565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.